CDISC

CDISC
Name	Clinical Data Interchange Standards Consortium
Abbreviation	CDISC
Type	Nonprofit
Headquarters	Tucson, Arizona
Founded	1997
Key people	Jerry Sheehan, Susan dosReis, Norm Goldfarb
Focus	Clinical research data standards

CDISC The Clinical Data Interchange Standards Consortium is an organization that develops global data standards to streamline clinical research and regulatory submissions. It produces models, implementation guides, and controlled terminologies used by pharmaceutical companies, biotechnology firms, contract research organizations, and regulatory agencies. Its standards interface with electronic health record initiatives, biostatistics methods, clinical trial operations, and data sharing platforms.

Overview

CDISC provides standardized structures for clinical trial information to enable interoperability among stakeholders such as Food and Drug Administration, European Medicines Agency, Pharmaceutical Research and Manufacturers of America, World Health Organization, and National Institutes of Health. Its work supports trial sponsors including Pfizer, Johnson & Johnson, Roche, Novartis, GlaxoSmithKline, AstraZeneca, Merck & Co., Sanofi, Bayer, AbbVie and Amgen, as well as contract research organizations like IQVIA, Parexel, Syneos Health, Labcorp and Charles River Laboratories. CDISC standards are adopted in data repositories and platforms operated by Duke University, Harvard University, Yale University, Stanford University, MIT, and global consortia such as TransCelerate Biopharma, All of Us Research Program, Global Alliance for Genomics and Health, and Observational Health Data Sciences and Informatics. Standards enable integration with analytical tools from SAS Institute, R Project for Statistical Computing, Python (programming language), JMP (software), Tableau Software, and cloud providers like Amazon Web Services, Microsoft Azure, and Google Cloud Platform.

Standards and Models

Key specifications include data models and terminologies used in submissions to authorities including Medicines and Healthcare products Regulatory Agency, Health Canada, and Pharmaceuticals and Medical Devices Agency. Prominent outputs include dataset models that map clinical observations to standards used alongside statistical analysis plans referenced in proceedings such as International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, ICH E3, ICH E9, ICH E6, and other regulatory guidances promulgated by European Commission. Technical elements interoperate with laboratory standards from Clinical and Laboratory Standards Institute and genomic frameworks from National Human Genome Research Institute. Data models align with electronic data capture systems produced by Medidata Solutions, Oracle Cerner, Epic Systems Corporation, and case report form templates used in initiatives like NIH Common Data Elements and CDISC Therapeutic Area User Guides.

Implementation and Tools

Implementation often uses software libraries and converters created by academic groups at University of Oxford, University of Cambridge, Johns Hopkins University, University of California, San Francisco, and industry tool vendors including PerkinElmer, BioClinica, Veeva Systems, and OpenClinica. Open-source projects hosted by communities such as GitHub and collaborations with consortia including Data Science Institute enable tooling for mapping, validation, and transformation to standards for analyses performed at Centers for Disease Control and Prevention, European Centre for Disease Prevention and Control, and large biobanks like UK Biobank and All of Us. Training and certification programs are delivered through partnerships with universities such as George Washington University and professional societies including Society for Clinical Data Management and International Society for Pharmacoeconomics and Outcomes Research.

Regulatory Acceptance and Use

Regulatory bodies such as Food and Drug Administration, European Medicines Agency, Health Canada, Pharmaceuticals and Medical Devices Agency, and Therapeutic Goods Administration reference standardized datasets in guidances and submission requirements for marketing authorization applications considered in panels like Advisory Committee on Immunization Practices and committees within Committee for Medicinal Products for Human Use. Standards are cited in guidances for electronic submissions and safety reporting used by sponsors filing with ClinicalTrials.gov, national regulatory submission gateways, and collaborative projects involving World Health Organization emergency use listings. Acceptance has driven harmonization across multinational trials run by consortia such as ENSURE and programs coordinated by Bill & Melinda Gates Foundation and Wellcome Trust.

History and Governance

Founded in 1997, the organization evolved with early engagement from pharmaceutical firms and regulatory representatives including stakeholders from Eli Lilly and Company, Bristol-Myers Squibb, Takeda Pharmaceutical Company, CSL Limited, Shionogi, and academic partners at Columbia University and University of Pennsylvania. Governance involves a board and advisory groups comprising representatives from industry, regulators, patient-advocacy organizations like Alzheimer's Association and American Cancer Society, and standards bodies including International Organization for Standardization and Health Level Seven International. Collaborative programs have involved projects with European Federation of Pharmaceutical Industries and Associations, Japanese Pharmaceuticals Manufacturers Association, and national institutes such as National Cancer Institute and National Institute of Allergy and Infectious Diseases. Milestones intersect with legislative and policy developments in regions overseen by European Commission and initiatives tied to 21st Century Cures Act and international harmonization forums like ICH.

Impact and Criticism

CDISC standards have facilitated reproducibility and pooled analyses by enabling meta-analyses across datasets curated by institutions like Cooperative Trials Group, International Cancer Genome Consortium, and registries such as Surveillance, Epidemiology, and End Results Program. Supporters cite efficiency gains in regulatory review processes experienced by sponsors such as Bristol-Myers Squibb and Novartis and improved data sharing in collaborations with The Lancet-featured studies and projects published by New England Journal of Medicine and Nature Medicine. Criticisms include resource burdens for smaller organizations and academic researchers at centers like State University of New York and University of Texas who cite costs similar to concerns raised in policy debates involving Congress of the United States, funding agencies like National Science Foundation, and research foundations. Other critiques address the complexity of mapping legacy data, interoperability challenges with electronic health record systems from Epic Systems Corporation and Cerner Corporation, and debates over intellectual property and licensing in contexts involving Open Source Initiative and standards governance discussed at forums such as International Conference on Biomedical Ontology.

Category:Clinical research standards